Tirzepatide is a groundbreaking treatment agent for individuals facing type 2 diabetes. As a dual stimulator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, promoting synergistic effects on blood glycemic control. By increasing insulin secretion along with reducing glucagon rele